Nevertheless, additional pre-clinical studies are needed in order to confirm these preliminary data and to further clarify the molecular mechanisms that are involved in AVPR2 antagonism, as well as the lowest effective dose of tolvaptan against cancer progression. The gene discussed is AVPR2; the disease is cancer.